{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:36:08Z","timestamp":1763415368073},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1248\/bpb.b15-00435","type":"journal-article","created":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T22:06:46Z","timestamp":1446329206000},"page":"1752-1756","source":"Crossref","is-referenced-by-count":12,"title":["Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids"],"prefix":"10.1248","volume":"38","author":[{"given":"Takumi","family":"Sakurada","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soji","family":"Kakiuchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institute of Biomedical Sciences, The University of Tokushima Graduate School"},{"name":"Department of Respiratory Medicine and Rheumatology, Institute of Biomedical Sciences, The University of Tokushima Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Tajima","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyushu University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Horinouchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Konaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Nishisako","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Teraoka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"},{"name":"Department of Clinical Pharmacy, Institute of Biomedical Sciences, The University of Tokushima Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yanagawa","sequence":"additional","affiliation":[{"name":"Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Institute of Biomedical Sciences, The University of Tokushima Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"},{"name":"Department of Clinical Pharmacy, Institute of Biomedical Sciences, The University of Tokushima Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). <i>Adv. Enzyme Regul.<\/i>, <b>38<\/b>, 135\u2013152 (1998).","DOI":"10.1016\/S0065-2571(97)00017-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Taylor EC, Patel HH. Synthesis of pyrazolo[3,4-<i>d<\/i>]pyrimidine analogues of the potent antitumor agent <i>N<\/i>-4-[2-(2-amino-4(3<i>H<\/i>)-oxo-7<i>H<\/i>-pyrrolo[2,3-<i>d<\/i>]pyrimidin-5-yl)ethyl]benzoyl-L-glutamic acid (LY231514). <i>Tetrahedron<\/i>, <b>48<\/b>, 8089\u20138100 (1992).","DOI":"10.1016\/S0040-4020(01)80479-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. <i>J. Clin. Oncol.<\/i>, <b>17<\/b>, 1194 (1999).","DOI":"10.1200\/JCO.1999.17.4.1194"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin <i>versus<\/i> cisplatin alone in patients with malignant pleural mesothelioma. <i>J. Clin. Oncol.<\/i>, <b>21<\/b>, 2636\u20132644 (2003).","DOI":"10.1200\/JCO.2003.11.136"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. <i>Oncologist<\/i>, <b>6<\/b>, 363\u2013373 (2001).","DOI":"10.1634\/theoncologist.6-4-363"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. <i>Br. J. Cancer<\/i>, <b>85<\/b>, 649\u2013655 (2001).","DOI":"10.1054\/bjoc.2001.2010"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Goedhals L, van Wiyk AL, Smith BL, Fourie SJ. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. <i>Int. J. Gynecol. Cancer<\/i>, <b>16<\/b>, 1172\u20131178 (2006).","DOI":"10.1111\/j.1525-1438.2006.00451.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. <i>Clin. Breast Cancer<\/i>, <b>2<\/b>, 47\u201351 (2001).","DOI":"10.3816\/CBC.2001.n.010"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Martin M, Spielmann M, Namer M, duBois A, Unger C, Dodwell D, Vodvarka P, Lind M, Calvert H, Casado A, Zelek L, Lluch A, Carrasco E, Kayitalire L, Zielinski C. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. <i>Ann. Oncol.<\/i>, <b>14<\/b>, 1246\u20131252 (2003).","DOI":"10.1093\/annonc\/mdg339"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. <i>Eur. J. Cancer<\/i>, <b>37<\/b>, 1366\u20131371 (2001).","DOI":"10.1016\/S0959-8049(01)00117-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Bajetta E, Celio L, Buzzoni R, Ferrari L, Marchian\u00f2 A, Martinetti A, Longarini R, Becerra C, Ilardi C, John W. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. <i>Ann. Oncol.<\/i>, <b>14<\/b>, 1543\u20131548 (2003).","DOI":"10.1093\/annonc\/mdg406"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Cripps C, Burnell M, Jolivet J, Batist G, Lofters W, Dancey J, Iglesias J, Fisher B, Eisenhauer EA. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. <i>Ann. Oncol.<\/i>, <b>10<\/b>, 1175\u20131179 (1999).","DOI":"10.1023\/A:1008372529239"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK, Thornton DE, Loehrer PJ. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. <i>Cancer<\/i>, <b>88<\/b>, 1807\u20131813 (2000).","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton D, Rowinsky E, Loehrer PJ Sr. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. <i>Ann. Oncol.<\/i>, <b>11<\/b>, 101\u2013103 (2000).","DOI":"10.1023\/A:1008305205159"},{"key":"15","unstructured":"15) National Comprehensive Cancer Network Guidelines. \u201cNon-Small Cell Lung Cancer.\u201d: \u2039http:\/\/www.tri-kobe.org\/nccn\/guideline\/lung\/english\/non_small.pdf\u203a, cited 1 May, 2015."},{"key":"16","unstructured":"16) National Comprehensive Cancer Network Guidelines. \u201cMalignant Pleural Mesothelioma.\u201d: \u2039http:\/\/www.tri-kobe.org\/nccn\/guideline\/lung\/english\/mpm.pdf\u203a, cited 1 May, 2015."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-na\u00efve patients with advanced-stage non-small-cell lung cancer. <i>J. Clin. Oncol.<\/i>, <b>26<\/b>, 3543\u20133551 (2008).","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"18","unstructured":"18) Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. <i>Mol. Cancer Ther.<\/i>, <b>1<\/b>, 545\u2013552 (2002)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Nakagawa K, Kudoh S, Matsui K, Negoro S, Yamamoto N, Latz JE, Adachi S, Fukuoka M. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. <i>Br. J. Cancer<\/i>, <b>95<\/b>, 677\u2013682 (2006).","DOI":"10.1038\/sj.bjc.6603321"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B<sub>12<\/sub> in previously treated patients with non-small cell lung cancer. <i>Clin. Cancer Res.<\/i>, <b>14<\/b>, 4206\u20134212 (2008).","DOI":"10.1158\/1078-0432.CCR-07-5143"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: A Phases I\/II Study in Japanese Patients. <i>Jpn. J. Clin. Oncol.<\/i>, <b>38<\/b>, 339\u2013346 (2008).","DOI":"10.1093\/jjco\/hyn024"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von Hoff DD. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. <i>Cancer Chemother. Pharmacol.<\/i>, <b>44<\/b>, 372\u2013380 (1999).","DOI":"10.1007\/s002800050992"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. <i>Nephron<\/i>, <b>16<\/b>, 31\u201341 (1976).","DOI":"10.1159\/000180580"},{"key":"24","unstructured":"24) Ishikawa H, Onishi T, Kobayashi R, Ohashi Y, Suzuki K, Yamamoto N, Shino M. Effectiveness of steroids for the rash side effect of pemetrexed. <i>Gan To Kagaku Ryoho<\/i>, <b>40<\/b>, 75\u201378 (2013)."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Bracke A, Van Marck E, Lambert J. Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction. <i>Clin. Exp. Dermatol.<\/i>, <b>34<\/b>, 337\u2013339 (2009).","DOI":"10.1111\/j.1365-2230.2008.02902.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Bosch-Barrera J, Gazta\u00f1aga M, Ceballos J, P\u00e9rez-Gracia JL, L\u00f3pez-Picazo JM, Garc\u00eda-Foncillas J, Ferrer M, Sanz ML, Pretel M, Idoate MA, Gil-Bazo I. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B<sub>12<\/sub> and folic acid supplementation for advanced non-small cell lung cancer. <i>Onkologie<\/i>, <b>32<\/b>, 580\u2013584 (2009).","DOI":"10.1159\/000232315"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Tummino C, Barlesi F, Tchouhadjian C, Tasei AM, Gaudy-Marqueste C, Richard MA, Astoul P. Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer. <i>Rev. Mal. Respir.<\/i>, <b>24<\/b>, 635\u2013638 (2007).","DOI":"10.1016\/S0761-8425(07)91133-X"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed <i>versus<\/i> docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. <i>J. Clin. Oncol.<\/i>, <b>22<\/b>, 1589\u20131597 (2004).","DOI":"10.1200\/JCO.2004.08.163"},{"key":"29","unstructured":"29) Hayashi A, Nakamura N, Matsumura C, Hirai M, Kagomoto M, Ishizu M. Assessment of risk factors of rash associated with pemetrexed therapy. <i>J. Jpn. Soc. Hosp. Pharm.<\/i>, <b>48<\/b>, 4 (2012)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. <i>J. Clin. Oncol.<\/i>, <b>24<\/b>, 552\u2013562 (2006).","DOI":"10.1200\/JCO.2004.00.9720"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/11\/38_b15-00435\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T05:07:43Z","timestamp":1567314463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/11\/38_b15-00435\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b15-00435","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}